Literature DB >> 3124179

5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse.

A J Bradbury1, B Costall, R J Naylor, E S Onaivi.   

Abstract

d-Amphetamine, in doses lower than required to increase motor activity, reduced mouse spontaneous locomotor activity when this was assessed using cages equipped with photocell units, using treadwheels, or the measurement of spontaneous climbing behaviour. Acute treatments with the serotonergic agonists quipazine and 5-hydroxy-DL-tryptophan also reduced wheel running activity, spontaneous locomotor activity assessed using photocell cages, and spontaneous climbing behaviour; fenfluramine caused a similar effect. Pretreatment with 5-hydroxy-DL-tryptophan enhanced the inhibitory effects of d-amphetamine. A 3-day treatment with fenfluramine, or lesions of the median raphe nucleus (but not the dorsal raphe nucleus) abolished the ability of d-amphetamine to reduce motor activity in the three test systems. It is concluded that low doses of d-amphetamine can reduce locomotor activity and that the effects may be mediated via an enhancement of the release of 5-hydroxytryptamine from the system arising in the median raphe nucleus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124179     DOI: 10.1007/bf00207235

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM.

Authors:  K FUXE
Journal:  Acta Physiol Scand Suppl       Date:  1965

2.  The role of the raphé and extrapyramidal nuclei in the stereotyped and circling responses to quipazine.

Authors:  B Costall; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1975-05       Impact factor: 3.765

3.  Long-term effects of fenfluramine on central serotonergic mechanisms.

Authors:  L R Steranka; E Sanders-Bush
Journal:  Neuropharmacology       Date:  1979-11       Impact factor: 5.250

4.  Amphetamine, apomorphine and investigatory behavior in the rat: analysis of the structure and pattern of responses.

Authors:  A E Kelley; M Winnock; L Stinus
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Increased sensitivity to d- and l-amphetamine action after midbrain raphe lesions as measured by locomotor activity.

Authors:  I Lucki; J A Harvey
Journal:  Neuropharmacology       Date:  1979-03       Impact factor: 5.250

6.  Hippocampal mediation of raphe lesion- and PCPA-induced hyperactivity in the rat.

Authors:  B L Jacobs; C Trimbach; E E Eubanks; M Trulson
Journal:  Brain Res       Date:  1975-08-29       Impact factor: 3.252

7.  Alteration of the neurochemical effects of fenfluramine by previous treatment with d-amphetamine.

Authors:  R N Hunsinger; M C Wilson
Journal:  Pharmacol Biochem Behav       Date:  1985-01       Impact factor: 3.533

8.  Activity, avoidance learning and regional 5-hydroxytryptamine following intra-brain stem 5,7-dihydroxytryptamine and electrolytic midbrain raphe lesions in the rat.

Authors:  S A Lorens; H C Guldberg; K Hole; C Köhler; B Srebro
Journal:  Brain Res       Date:  1976-05-21       Impact factor: 3.252

9.  Spontaneous and delayed spatial alternation following damage to specific neuronal elements within the nucleus medianus raphe.

Authors:  K E Asin; H C Fibiger
Journal:  Behav Brain Res       Date:  1984-09       Impact factor: 3.332

10.  Action of fenfluramine on monoamine stores of rat tissues.

Authors:  E Costa; A Groppetti; A Revuelta
Journal:  Br J Pharmacol       Date:  1971-01       Impact factor: 8.739

View more
  8 in total

1.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

2.  Influences of activity wheel access on the body temperature response to MDMA and methamphetamine.

Authors:  N W Gilpin; M J Wright; G Dickinson; S A Vandewater; J U Price; M A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2011-05-13       Impact factor: 3.533

3.  Cross-familiarisation conditioned taste aversion procedure as a method to reveal stimulus resemblance between drugs: studies on the 5-HT1A agonist 8-OHDPAT.

Authors:  R De Beun; H W Rijk; C L Broekkamp
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

5.  A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.

Authors:  Michelle L Miller; Amira Y Moreno; Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Brittani D Vaillancourt; M Jerry Wright; Kim D Janda; Michael A Taffe
Journal:  Biol Psychiatry       Date:  2012-10-23       Impact factor: 13.382

6.  Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone).

Authors:  M L Miller; K M Creehan; D Angrish; D J Barlow; K L Houseknecht; T J Dickerson; M A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-07-23       Impact factor: 4.492

7.  Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity.

Authors:  Ryszard Brus; Przemyslaw Nowak; Ryszard Szkilnik; Urszula Mikolajun; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

8.  Cell-Type Specific Deletion of CB2 Cannabinoid Receptors in Dopamine Neurons Induced Hyperactivity Phenotype: Possible Relevance to Attention-Deficit Hyperactivity Disorder.

Authors:  Ana Canseco-Alba; Branden Sanabria; Mariam Hammouda; Rollanda Bernadin; Marizel Mina; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Front Psychiatry       Date:  2022-02-08       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.